Loading
Tumours starved of oxygen produce a chemical that switches immune cells off. A scan can show which tumours are starved, and those are the ones to treat with blockers.
Hypoxia drives CD73-mediated adenosine production and A2A receptor signalling that suppresses T cells and natural killer cells. Adenosine-axis drugs have given inconsistent phase 2 results in unselected populations. Hypoxia PET tracers and validated hypoxia gene signatures could select the patients whose tumours actually run this pathway.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, RNA sequencing & expression profiling, Biomarkers are not validated or standardised.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Renal cell carcinoma, Immune checkpoint inhibitors.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy, Renal cell carcinoma.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy, Immune checkpoint inhibitors.
Shares Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy, Renal cell carcinoma, Immune checkpoint inhibitors.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy, Immune checkpoint inhibitors.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Renal cell carcinoma, Immune checkpoint inhibitors.